```
UNITED STATES DISTRICT COURT
   SOUTHERN DISTRICT OF NEW YORK
 2
 3
   GREGORY MARONEY,
                            Plaintiff,
 4
 5
                                            7:20-CV-02788 (CS) (JCM)
        -vs-
 6
                                            TELECONFERENCE
 7
   KSF ACQUISITION CORPORATION,
 8
                            Defendants.
 9
10
        *Proceedings recorded via digital recording device*
11
12
                                 United States Courthouse
                                 White Plains, New York
13
                                 Thursday, March 3, 2022
14
15 Before:
                                 HONORABLE JUDITH C. McCARTHY
16
                                 Magistrate Judge
17
18 APPEARANCES:
19 BURSOR & FISHER, P.A.
       Attorneys for Plaintiffs
20 BY: ANDREW OBERGFELL, ESQ.,
21
   GREENBERG TRAURIG, LLP
22
       Attorneys for Defendant
   BY: RICK L. SHACKLEFORD, ESQ.
23
        PHILIP H. COHEN, ESQ.
        ANDREA N. CHIDYLLO, ESQ.,
24
25
```

2

```
THE DEPUTY CLERK: This is the matter of Gregory
 1
   Maroney versus KSF Acquisition Corporation.
 2
 3
             Counsel, state your appearances for the record.
 4
             MR. OBERGFELL: Good morning, your Honor. This is
   Andrew Obergfell for the Plaintiff, Gregory Maroney.
 6
             THE COURT: Good morning.
 7
             MR. SHACKLEFORD: Good morning, your Honor. Rick
   Shackleford with Greenberg Traurig for Defendant KSF Acquisition
   Corp.
 9
             MR. COHEN: Good morning, your Honor. Philip Cohen,
10
   Greenberg Traurig, for KSF Acquisition Corp.
11
12
             MS. CHIDYLLO: Good morning. Andrea Chidyllo,
13
   Greenberg Traurig, for Defendant KSF Acquisition Corp.
             THE COURT: Good morning, Counsel.
14
15
             So we had a conference on -- just a little while ago,
16
   about a month, on February 3rd, and I have received -- there
   were some issues that were -- that you brought up then and I've
17
   received letters, Docket 50 and 51, which I have reviewed.
18
   know there were two issues raised in Docket 51. One was an
19
20
   attorney/client privilege. I understand that is no longer an
21
   issue for the Court, but the e-discovery, scope and completion,
22
   remains an issue.
23
             Is that correct?
24
             MR. OBERGFELL: Yes, your Honor.
25
             MR. SHACKLEFORD: Yes, your Honor.
```

3

1 THE COURT: Okay. Before we go into that, can you tell me also what has happened since we last spoke. 2 3 MR. OBERGFELL: Your Honor, this is Andrew Obergfell for the Plaintiff. 5 As your Honor would recall, after the last conference, Defendant was to provide hit counts for our revised search terms, which we had provided shortly before the last conference. We received that hit report on February 17th, so two weeks after the conference before your Honor. As soon as we received that new hit report from Defendant, you know, we provided a proposal 10 to limit the overall number of hits and strings, and we provided 11 12 that proposal, I think, either the same day or the day after and 13 we have one string that's still in dispute which we're talking 14 about today, and, as I understand it, Defendant is in the process of reviewing documents associated with those strings, or 15 at least will be in the near future. 16 17 There was also a challenge to the privilege -- some of the privilege designations as your Honor referenced, and I think 18 those documents were produced last night by Defendant, but, you 19 20 know, the main issue is, you know, completing this document 21 production. You know, we haven't seen the, you know, the documents associated with, you know, the search term hits at 22 23 issue, so I think that's, that's the main issue right now. 24 THE COURT: Okay. So let me hear arguments on -- and 25 I believe that the only issue is the search terms as it relates

```
to line 6? Or row 6?
 2
             MR. OBERGFELL: Yes, your Honor, that's MCT oil and
   coconut oil linked with label or labeling?
 3
 4
             THE COURT: Yep. And this hit list has that at
   getting 7,504 hits.
 6
             MR. OBERGFELL: That's correct, your Honor.
 7
             THE COURT: Okay.
                                So I want to hear arguments on
   why...each side's position.
 9
             MR. OBERGFELL: Yes, your Honor, and, again, this is
10
  Andrew Obergfell for the Plaintiff.
11
             So basically, your Honor, when we're dealing with, you
12
   know, production of ESI, you know, it's black letter law, you
13
   know, in this district that -- it's a two-step inquiry, one, is
14
   there good cause, you know, for the production of the requested
   discovery and is there a commensurate burden counterbalancing
15
   that, you know, that inquiry, the good-cause inquiry.
16
17
             On the question of good cause, you know, the very
   heart of this case, your Honor, is about the label of the
18
   product and specifically the ingredient MCT oil, otherwise known
19
20
   as coconut oil, and whether the label claims associated with
21
   that ingredient are substantiated, namely does the MCT oil
   result in weight loss, does -- is it clinically proven, and so
22
23
   these search terms were targeted to understand the communication
24
   surrounding the labeling of the product, and also relevant to
25
   that is that, you know, there's an fraud claim, there's GBL
```

Teleconf.

25

Maroney v. KSF

5

claims in this case, and Defendant's knowledge of the efficacy of the MCT oil and knowledge of whether or not the labeling was false or deceptive is directly at issue in this case, and that's why we provided that search term, to link up the challenged ingredient with the actual labeling of the product. 6 Now, Defendant says, "well, MCT oil is an ingredient 7 in a number of our products," and that much is true. However, Defendant sought to limit the string by, you know, including the term 'caprylic,' and caprylic acid is essentially a component on 10 of MCT oil. However, we think that that would too...much -would narrow the scope of the search so much that potentially 11 12 very relevant information would be omitted. 13 For example, one could imagine an e-mail string where, 14 you know, two employees are discussing and saying, you know, MCT oil doesn't really result in weight loss and maybe we shouldn't 15 put it on the label. That communication would be captured by 16 17 our proposed search term, it would not be captured by Defendant unless they used the term 'caprylic,' which is a fringe term 18 19 that's unlikely to be used probably in modern -- you know, in 20 common discourse between employees. 21 So we think given the, the low number of overall hits compared to the fact that this is a nationwide class action and 22 23 that the fact that this string seems to look at exactly what's 24 at issue in this case, namely the labeling and the MCT oil and

coconut oil ingredients specifically, that we think that our

6

```
string should be searched and relevant documents associated with
   that string should be produced because, you know, it strikes
   right at the heart of the case.
 4
             And weighed against that is Defendant has not
   identified any specific burden in actually reviewing the
   documents associated with this string and producing what's
   relevant, and it's clear in this district, you know, based on
   case law that a claim of undue burden has to be substantiated by
   evidence, by affidavits, things of that nature, which Defendant
10
   could have provided to this Court, but they didn't, so we have
   what we think is a very relevant string and a proposed
11
12
   limitation by Defendant that would leave out highly --
13
   potentially highly relevant information, and, you know, weighed
   against no real proposed burden by Defendant, we think that that
14
   string, you know, should be searched.
15
16
             And I'd also note that, you know, we've met and
17
   conferred and we provided what we think is a pretty reasonable
18
   limitation on what was the overall number of hits based on our
   terms and we're really just trying to get to the brass tacks of
19
20
   what's relevant in this case.
             THE COURT: Do we know what the hit would be if we
21
   added the word 'caprylic'?
22
23
             MR. OBERGFELL: I do not know that information, your
24
  Honor. Perhaps Defendant does, though.
25
             THE COURT:
                         Okay.
```

```
Who wants to speak on behalf of Defendant?
 1
 2
             MR. SHACKLEFORD: This is Rick Shackleford, your
   Honor. I'll take the main mode, but the question that the Court
 3
   asked directly, Ms. Chidyllo may know the answer to that
   question, so I would defer to her on that before I weighed in.
                                 I do not -- this is Ms. Chidyllo.
 6
             MS. CHIDYLLO: Hi.
 7
   I do not know the answer, but I'm going to see if I can figure
   it out as we're speaking here.
 9
             THE COURT: Okay. Mr. Shackleford, you can continue.
10
             MR. SHACKLEFORD: Yes, thank you, Your Honor, and I'd
   like to begin by complimenting Counsel.
11
             I think the meet-and-confer efforts in this case have
12
13
   been productive, we had a conversation yesterday, so I think
14
   we're moving things along and I, I hope the Court appreciates
   that we are continuing to try to narrow the issues, so we've
15
16
   resolved the privilege issue, we've dealt with some other stuff
17
   and trying to minimize, you know, the time that we have to take
   up on your Honor's calendar.
                                 There are a couple things, though,
18
   that were said that I would push back on, because I think it's
19
20
   important to frame what the case is really about.
21
             The case is about coconut oil as a standalone product,
   and I think it's -- you can understand why we're having the
22
23
   problem with this limitation if you just substitute the word
24
   'butter' for 'coconut oil.' If I sold the product claiming
25
   butter as a standalone is an effective dietary supplement and
```

Teleconf.

Maroney v. KSF

you should just take butter and eat butter as a standalone and you'll lose weight and I get sued over that and I'm hit with discovery asking for every product in an entire line of products that uses butter as an ingredient, you get a sense of why it is that we're having the problem we're having.

The case is about a unique dietary supplement, MCT oil, and we've proposed a limiter, and there's no dispute that the limiter would be unique to sorting out documents and communications limited to the only product that's at issue, but what Plaintiff wants to do is sweep in everything that uses coconut oil as an ingredient. It's a fat in food product, it's used in lots of different things, and whether as a fat in a meal replacement bar or some other product and whether that different product may be effective for weight loss by using that fat as opposed to a different fat is completely unrelated to the claim here that's applied to the single standalone product that has one ingredient, so that's why we proposed the limiter that we did.

And so regardless of -- you know, is the burden insurmountable? I think the case law supports the notion that you compare the burden with what is the value of the discovery that's at issue. That lies at the heart of proportionality, what is the relative need versus the relative burden, so whether the burden is enormous in the abstract as a standalone proposition is different in a comparison between the burden and

(

This feels like discovery for the sake of the de minimus value. 2 discovery. I would ask what fact in issue is going to be made 3 more likely to be demonstrated by information pertaining to thirty other products, and I believe that is the count, thirty other products, that use coconut oil as an ingredient, and it has to be listed on the label if it's used as an ingredient whether there's any claim made about the coconut oil or not, so that's why we proposed the limiter that we did. We think it 10 makes imminent sense in the circumstances, it is appropriately tailored to the facts at issue in the case and weeds out things 11 12 that aren't at issue and can't possibly be at issue. 13 So that's why we have developed the limiter that we 14

So that's why we have developed the limiter that we have, and we believe -- and we're happy to run the search, review the documents, produce whatever's responsive, but that's why we're here, that's the one thing as of today that we haven't been able to resolve.

15

16

17

18

19

20

21

22

23

24

25

THE COURT: So tell me, how do you address the fraud issue that Plaintiff is saying, that it goes to, you know, what the knowledge that Defendants had?

MR. SHACKLEFORD: Well, there's no claim made on the other products that the use of coconut oil is what makes the difference in a snack bar or a meal replacement or some other product. That's where we address the issue, so there would be no fraud claim. It's just not relevant to that. The issue is

-

```
whether this dietary supplement as a standalone is, you know,
   clinically proven to promote weight loss. That's his theory.
 2
   Not that I've used the entire keto diet and you've used coconut
   oil as a key component of it. It's just one product.
 5
             So, again, I go back to butter. I may or may not
  believe butter as a standalone is great, but there's lots and
   lots of other reasons why one would use butter as an ingredient,
   as a fat, in a completely different product.
 9
             MR. COHEN: Your Honor, it's Philip Cohen.
10
             Just to add to Mr. Shackleford's point, we do have an
   unlimited search with respect to 'clinically proven' and 'oil'
11
12
   and 'MCT oil' and 'coconut oil.' We're running that search,
13
   we're doing that search. The only one that we're looking for
   the limitation on is the search that includes the label, so if
14
   there's anything that relates to clinically proven and this
15
16
   product, it will be captured.
17
             THE COURT: Mr. Obergfell.
18
                            Yes, your Honor, I'd like to just
             MR. OBERGFELL:
19
   address a few points there.
20
             The first is that in terms of the proposed limiter,
   it's incorrect to say that the term 'caprylic' only appears on
21
22
   this specific product because caprylic acid is a component of
23
   MCT oil and it's, at least as far as the SlimFast company is
24
   concerned, considered to be a beneficial ingredient. It does
25
   appear on at least on one other product and that's the
```

ready-to-drink shakes, so that it's just the fact of the matter that it is true that there is going to be -- you know, this ingredient is, is across different product lines. However, this particular product is literally called MCT oil, so it's difficult to pinpoint this product in a more specific way. 6 And, your Honor, the bottom line is, I provided a 7 hypothetical in my original presentation and that is that, for example, if there is an e-mail correspondence that says "MCT oil does not contribute to weight loss and, therefore, we can't put 10 it on the label," just imagine that was in an e-mail, that would be directly relevant to our claims regarding the -- tying the 11 12 MCT oil to purported weight loss, which is exactly what the 13 challenge label is, clinically proven to lose weight and keep it 14 So I appreciate that Defense Counsel has searched the clinically proven aspect of it, that is one aspect of it, but 15 16 another aspect of it is the weight-loss aspect, and if you read Judge Seibel's decision on the MTD, you know, she found it to be 17 18 plausible that, you know, a reasonable consumer could believe 19 that consuming the MCT oil could lead to weight loss and 20 maintain weight loss, so we're entitled to take discovery on that issue. 21 22 Now, I'm sympathetic to the fact that there could be 23 some overlap with other products, but I can't have a situation 24 where evidence like that, communications like that, are left out 25 of the production because of an artificial limiter of the term

'caprylic' which may or may not appear, so the essence of the dispute is that I can't live with the fact that that kind of evidence may be left out of the search for the benefit of a marginally lower hit count. 5 THE COURT: Mr. Shackleford? 6 MR. SHACKLEFORD: It is utterly conjectural and 7 We can invent all sorts of hypothetical scenarios speculative. of what might happen or what might be there and we can do it until we're blue in the face. The reality remains that it's a one-sided burden and it's a one-sided expense to chase down 10 these, you know, rainbow unicorns. 11 12 Again, I come back to the point that this is about not 13 coconut oil, not MCT oil. If this were a case about MCT oil, 14 they would have pled it differently and they would have implicated other products. This is a case about a single 15 product and whether this single product used all by itself is 16 17 clinically support -- clinically proven to support weight loss. That's the theory. Plaintiff is the master of his own theory, 18 19 that's what he pled, but once you do that, there are 20 implications that are going to confine the four corners of 21 discovery, so living within the four corners of the complaint, you're suing over this specific product, let's limit the 22 23 discovery to this specific product. That's the point of the 24 limitation that we've suggested. 25 And what you've just heard is that there might be all

```
other kinds of things talking about all kinds of other products
   out there with different ingredients, different functions,
   different uses, that aren't at issue in the case. He's chosen
  his theory; let's conduct discovery consistent with the four
   corners of the complaint.
             THE COURT: And, Ms. Chidyllo, did you find out what
 6
 7
   the hit -- how the hit would change?
             MS. CHIDYLLO: I do not believe we have that row with
 8
   caprylic and what that row's change would be now. We'd have to
   get that information.
10
11
             THE COURT: So I am going to...let me just look at
12
   your letter for a second.
13
             (Brief pause)
14
             THE COURT: I'm going to deny Plaintiff's request and
   allow Defendants to add the term 'caprylic' to it without
15
   prejudice to come back if you should find things in what has
16
   been produced in all of the production that would lead you to
17
   believe that there was something that might be missing that you
18
19
  need.
20
             This isn't the only form of discovery in this case.
   You're going to be able to ask, you know, to witnesses what they
21
22
   understood and, you know, what they understood about the MCT oil
23
   and it as a standalone product. You are looking at one product
24
  here, not the oil in all products, not the labeling in all
25
   products. It's just in this one product.
```

I do believe when you're looking at proportionality, 1 it's not just did it have good cause and is it a burden, it's 2 really you're supposed to be weighing it on kind of the relevance, needs of the case, and whether it's proportional to, to both the need and the burden it'll have on. I don't believe -- you know, you're getting a lot of documents. You're going to get a lot of documents you're going to be reviewing. I don't think that narrowing this is going to limit you from getting something that you need in this case. As I said, if you find that something in the other 10 production reinforces your need to change it or something in 11 12 this production, it goes down too dramatically, you know, forces 13 your need to change it, then we can discuss it, it's without prejudice for you to come back, but I don't see -- I believe 14 you're getting what you need to determining the facts of this 15 case, what the Defendants knew, and you'll have an opportunity, 16 17 also, to depose people to find out what they knew, what they believed, when they were involved in the labeling, and what they 18 19 were writing on the label. 20 So I must ask you, how are you doing for production, you know, discovery? You have fact depositions April 29th. 21 22 When do you think we're going to get past this...document 23 discovery? 24 MR. OBERGFELL: Your Honor, I'd have to defer to 25 Defendant on that because they're currently running the searches

```
right now, but I agree timing is an issue.
 2
             THE COURT: Counsel for Defendants, who wants to
   address this?
 4
             MR. SHACKLEFORD: I'll start, your Honor. We continue
   to work diligently on it. As we explained in our letter brief
   last week, it is a small in-house legal department and obviously
   they have other cases and other demands on their time. I spoke
   with Mr. Obergfell yesterday, we are certainly amenable, and if
   it's necessary and happy to do it today, to modify the
   scheduling order.
10
11
             We really have two currencies that you deal with in
12
   completing discovery, time and money, and if there's no
13
   prejudice and we're mindful of the Court's schedule and the
14
   burden it creates by moving things around, but if extra time is
   necessary and reasonable time, you know, we talked about a
15
   notion of 60 days to make sure that the documents are reviewed,
16
   produced, and the Plaintiff has enough time to, you know, review
17
   them, simulate them, decide the questions to ask of witnesses
18
19
   and be able to do that in an orderly fashion.
20
             The other currency's money. If you do that to meet a
   deadline, then it increases the cost and the burden of trying to
21
22
   get it within the deadline, and not to suggest that time is
23
   cheaper than money, but sometimes in the circumstances, that's a
24
   reasonable accommodation to make, but we are proceeding a pace.
25
             THE COURT: So you don't know when it's going to be
```

```
produced.
 2
             MR. SHACKLEFORD: Since I don't have them in my hands
   personally, I can't tell you.
 3
 4
             THE COURT: Can you tell me what schedule they're
   working on, what kind of resources they're committing to it,
   whether it's a priority or not a priority...
 7
             MR. SHACKLEFORD: It's absolutely a priority, and we
   are on the phone several times a week with our counterparts in
   the in-house legal department. Their IT department is located
10
   in Ireland, so we deal with some lengthy time zone differences,
   as well as getting information and the review of the documents,
11
12
   but that's -- you know, it's ongoing. It hasn't been set aside
13
   in deference to other things, but by the same token, it's not
   the only thing on the legal department's plate.
14
15
             THE COURT: I'm disinclined to give you any extension
16
   of time right now. 4/29 is 60 days from now. If I give you
17
   another 60 days, I'm giving you 120 days to do this and you have
   no idea whether you're going to need that or not, and my
18
   experience is if you get it, you use it, and so you're not
19
20
   getting it.
21
             I want you to continue working on this at pace, we're
   going to talk in 30 days, and you are going to give me a report.
22
23
   I would expect by that point -- and I would expect that there
24
  would be rolling production and that you don't wait until
25
   everything is reviewed, which, you know, I would expect there's
```

rolling production from the client to you and from you to the Plaintiff. There's no need to, you know, hold up -- yes, of course, you know, if you've only looked at a hundred documents, there's no need to do tranches of a hundred, but you shouldn't hold up until everything's done, so...you are likely to need more time, but you really don't know what you need at this point and I want to keep a little bit of pressure on you. 8 I appreciate the fact that the team is, you know...diligently working as you described it. I don't want 10 that to change, and I want them to know that you have to report to me in four weeks that, you know, where's everything at, how 11 12 much has been produced, and my hope is that I do not hear 13 "nothing" and that I hear "everything" or "almost everything" at that time. Four weeks should be enough time to -- you know, if 14 you're really diligently working on it. 15 I know people have other jobs, other responsibilities, 16 not other jobs, but other responsibilities, but if time is spent 17 every day on it, they can get through the documents. 18 19 MR. SHACKLEFORD: I appreciate that, your Honor. 20 will be the report out, that we remain under the, the current 21 schedule and need to be working diligently to meet that, and I 22 fully expect next time we talk to you that if it's not 23 completed, I will be able to give you a date certain by when it 24 will. 25 THE COURT: Yeah, and when I have that, I can have a

```
better sense of what you need and Mr. Obergfell can have a
  better sense of what he needs and can tell the Court, "yeah, I
  need X because I'm going to do X many depositions" and "I've
   just got the documents" or "I've only reviewed half of them," et
   cetera, so let's talk in a month from now.
             Ms. Hummel, I think a month from now I have
 6
 7
   (inaudible) conference, so let's talk the week after that.
 8
             THE DEPUTY CLERK: So you're available on the 11th at
   eleven.
10
             THE COURT: April 11th at eleven a.m.? Does that work
11 for everyone?
12
             MR. OBERGFELL: That should be work for Plaintiff,
13
  your Honor.
14
             MR. SHACKLEFORD: Again, your Honor, we'll get it
   covered. We've got three of us, so somebody will be able to
15
16
   talk to you on the 11th.
17
             THE COURT: Okay, so we will talk on April 11th at
   eleven a.m.
18
19
             Thank you, everyone.
20
             MR. OBERGFELL: Thanks, your Honor.
21
             MR. SHACKLEFORD: Thanks, your Honor.
22
             THE COURT: Be well.
23
             MS. CHIDYLLO: Thank you.
24
25
```

```
1 Certified to be a true and accurate
 2 Transcript of the digital electronic
 3 Recording to the best of my ability.
 4
 5 Tabitha R. Dente, RPR, RMR, CRR
 6 U.S. District Court
  Official Court Reporter
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```